{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:40:01Z","timestamp":1793090401373,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105627","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:03:11Z","timestamp":1790434991000},"page":"105627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reassessing the clinical value of momelotinib in myelofibrosis: An ESMO-MCBS:H\u2013based appraisal of SIMPLIFY-1 and MOMENTUM"],"prefix":"10.1016","volume":"227","author":[{"given":"S.A.L.","family":"Wever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hoogendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Van Rijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.E.","family":"Oortgiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ammatuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105627_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.14740\/jh2094","article-title":"Efficacy and safety of momelotinib in myelofibrosis: a systematic review and meta-analysis with a focus on anemia outcomes","volume":"14","author":"Al-Nusair","year":"2025","journal-title":"J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1515\/cclm-2020-0928","article-title":"Optimizing hepcidin measurement with a proficiency test framework and standardization improvement","volume":"59","author":"Aune","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.critrevonc.2026.105627_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105627_bib5","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178012","article-title":"Anemia and transfusion dependency are important prognostic factors for overall survival in patients with myelofibrosis: results of a real-world analysis of medicare patients","volume":"142","author":"Gerds","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105627_bib6","first-page":"1","article-title":"Pharmacy and transfusion costs of ruxolitinib and momelotinib in patients with myelofibrosis and anemia","author":"Gerds","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2026.105627_bib7","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2015-12-639112","article-title":"Hepcidin in the diagnosis of iron disorders","volume":"127","author":"Girelli","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105627_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105627_bib9","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105627_bib10","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib11","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000611","article-title":"EHA evaluation of the ESMO-magnitude of clinical benefit scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies","volume":"5","author":"Kiesewetter","year":"2020","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105627_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.annonc.2023.06.002","article-title":"ESMO-magnitude of clinical benefit scale for haematological malignancies (ESMO-MCBS:H) version 1.0","volume":"34","author":"Kiesewetter","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ejh.70034","article-title":"Efficacy of momelotinib in myelofibrosis patients: results from a multicenter study","volume":"116","author":"Martorelli","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16234067","article-title":"Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials","volume":"16","author":"Masarova","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105627_bib16","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1080\/14796694.2024.2368450","article-title":"Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM","volume":"20","author":"Masarova","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib17","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1080\/14796694.2025.2511562","article-title":"Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis","volume":"21","author":"Masarova","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib18","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/14796694.2025.2511564","article-title":"Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis","volume":"21","author":"Masarova","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000966","article-title":"Patient-reported outcomes and quality of life in anemic and symptomatic patients with myelofibrosis: results from the MOMENTUM study","volume":"7","author":"Mesa","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2026.105627_bib20","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2026.105627_bib22","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105627_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.annonc.2022.12.004","article-title":"Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit","volume":"34","author":"Oosting","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.23406","article-title":"Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis","volume":"88","author":"Pardanani","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103862","article-title":"Anemia in myelofibrosis: current and emerging treatment options","volume":"180","author":"Passamonti","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-025-01275-z","article-title":"Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study","volume":"15","author":"Perez-Lamas","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105627_bib27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ajh.70203","article-title":"Post-FDA approval experience with momelotinib in JAK inhibitor-naive myelofibrosis: focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy","volume":"101","author":"Tefferi","year":"2026","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105627_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105627_bib31","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105627_bib32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105627_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70018","article-title":"Momelotinib: mechanism of action, clinical, and translational science","volume":"17","author":"Vlasakakis","year":"2024","journal-title":"Clin. Transl. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:08:44Z","timestamp":1793088524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"alternative-id":["S1040842826005147"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105627","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reassessing the clinical value of momelotinib in myelofibrosis: An ESMO-MCBS:H\u2013based appraisal of SIMPLIFY-1 and MOMENTUM","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105627"}}